mRNA-1273 for Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Fred Hutchinson Cancer Research Center, Seattle, WA
Lymphoma+6 More
mRNA-1273 - Biological
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Boost...

See full description

Eligible Conditions

  • Lymphoma
  • Solid Tumor Malignancies
  • Malignancies, Hematologic
  • Leukemia
  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether mRNA-1273 will improve 3 primary outcomes and 1 secondary outcome in patients with Lymphoma. Measurement will happen over the course of 14 months.

14 months
Assess immunogenicity of m-RNA 1273 administered in 2 doses
Safety and reactogenicity of MRNA-1273 of a booster vaccination
Safety and reactogenicity of MRNA-1273 vaccine
immunogenicity of mrna-1273 vaccine as assessed by neutralizing antibody (nAb)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

1
1 of 2
2
1 of 2
Experimental Treatment

This trial requires 220 total participants across 2 different treatment groups

This trial involves 2 different treatments. MRNA-1273 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

1100 mcg (0.5 mL) mRNA-1273 injection (IM) on days 1 and 29; with option for subsequent booster dose(s), 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29
2100 micrograms (0.5 mL) mRNA-1273 injection on D1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Moderna COVID-19 Vaccine
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 14 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 14 months for reporting.

Closest Location

Fred Hutchinson Cancer Research Center - Seattle, WA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Participants must meet all the inclusion criteria in order to be eligible to participate in the study.
Histologically or cytologically confirmed solid tumor receiving a standard of care PD1/PDL1 inhibitor for treatment of their solid tumor (inclusive of Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma particpants receiving PD1/PDL1 inhibitors as standard of care therapy)
Confirmed diagnosis of acute leukemia (myeloid (AML) or lymphoid (ALL) or other acute leukemia; multiple myeloma; Waldenstrom macroglobulinemia
Confirmed diagnosis of lymphoma, including small lymphoblastic lymphoma (i.e.,chronic lymphocytic leukemia)
Be post allogeneic stem cell transplantation (for any indication)
Be an adult patient (aged 18 or older) with any malignancy who does not fit any of the above categories
Age >=18 years.
Absolute lymphocyte count-Minimum value of 200 cells per mcL
Absolute neutrophil count-Minimum value of 500 cells per mcL
Platelets-Minimum value of 25,000 cells per mcL

Patient Q&A Section

How many people get multiple myeloma a year in the United States?

"Findings from a recent study suggests that MM incidence is relatively constant in the United States, although in some parts of the country, incidence may be significantly increased. Furthermore, MM seems to be increasing in some states. Findings from a recent study suggest that the data from MM-HOD may be skewed since patients with MM were excluded from the analysis. Despite these limitations, our analysis still suggests an MM incidence that is similar to that of previous studies in other geographic areas." - Anonymous Online Contributor

Unverified Answer

Can multiple myeloma be cured?

"Currently, there are not any agents on the market that can cure myeloma. There are three approaches to myeloma therapy: observation, targeted therapy based on bortezomib, and induction and maintenance therapy with BZDs and ASCT. If there is no indication of treatment or an effective response to therapy, transplantation can be attempted in a selected group of patients with minimal disease." - Anonymous Online Contributor

Unverified Answer

What is multiple myeloma?

"Multiple myeloma is an aggressive cancer that is a disease that is associated with an increased rate of skeletal fractures, blood clotting problems and increased risk of death. Multiple myeloma can be prevented through a number of measures for prevention, early detection and management of the disease." - Anonymous Online Contributor

Unverified Answer

What are common treatments for multiple myeloma?

"There is significant variability in the treatment given to MM patients and the type of therapy, with a number of options available. Treatment is reliant on the diagnosis and the stage of the disease. A number of factors such as age, function, weight, and comorbid conditions are considered when managing treatment." - Anonymous Online Contributor

Unverified Answer

What causes multiple myeloma?

"In a country where multiple myeloma accounts for less than 1% of all malignancies, these data suggest that screening of an otherwise healthy person for multiple myeloma should be offered to all older women." - Anonymous Online Contributor

Unverified Answer

What are the signs of multiple myeloma?

"The presence of bone pain is a very strong predictor of multiple myeloma, and patients can detect the disease based on these signs without further investigations." - Anonymous Online Contributor

Unverified Answer

Is mrna-1273 typically used in combination with any other treatments?

"Both mrna-1273 and mrna-2905 could be used in the treatment of myeloma patients, but there were minimal differences in the clinical responses and overall survival between these two protocols. Further studies are required to establish mrna-1273 as an additional treatment component in myeloma patients, and the clinical outcomes for this combination seem satisfactory." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for multiple myeloma?

"The number of patients is not significant enough at present for randomized treatments. Although it is necessary to test new medications, the new data need to be tested in patients. In addition, new clinical drugs will need to be tested to find the best way to treat multiple myeloma." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of multiple myeloma?

"In a recent study, findings of a large number of patients with multiple myeloma, the primary cause of the disease was biclonal gammopathy of undetermined significance. The development of multiple myeloma from biclonal gammopathy of undetermined significance was associated with IgM and IgG b-cells." - Anonymous Online Contributor

Unverified Answer

Does mrna-1273 improve quality of life for those with multiple myeloma?

"Those with MM treated with mrnaside therapy had a statistically significant improvement in quality of life after 6 months compared with conventional treatment, as measured using a quality of life questionnaire." - Anonymous Online Contributor

Unverified Answer

What does mrna-1273 usually treat?

"Results from a recent paper provide clinical evidence that RNAi may be a useful therapy as a monotherapeutic agent for the treatment of multiple myeloma-related disease." - Anonymous Online Contributor

Unverified Answer

Does multiple myeloma run in families?

"This pedigree expands upon previous observational studies, indicating that multiple myeloma is a heritable disease. Results from a recent clinical trial also suggests that the prevalence of multiple myeloma may vary between geographic regions." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Lymphoma by sharing your contact details with the study coordinator.